The present invention provides a transgenic non-human animal whose genome
comprises a disruption in its endogenous PDE7A gene, wherein the
transgenic animal exhibits decreased expression of functional PDE7A
protein relative to wild-type. The present invention further provides a
method for creating a transgenic non-human animal exhibiting decreased
expression of functional PDE7A protein relative to wild-type. Finally, the
present invention provides a method for screening a PDE7A inhibitor for at
least one side-effect.
